Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial

JAMA : the Journal of the American Medical Association
Keith S KayeEvangelos J Giamarellos-Bourboulis

Abstract

Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections. To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. Phase 3, multicenter, multinational, randomized clinical trial (TANGO I) conducted November 2014 to April 2016 and enrolling patients (≥18 years) with complicated UTI, stratified by infection type and geographic region. Eligible patients were randomized 1:1 to receive meropenem-vaborbactam (2g/2g over 3 hours; n = 274) or piperacillin-tazobactam (4g/0.5g over 30 minutes; n = 276) every 8 hours. After 15 or more doses, patients could be switched to oral levofloxacin if they met prespecified criteria for improvement, to complete 10 days of total treatment. Primary end point for FDA criteria was overall success (clinical cure or improvement and microbial eradication composite) at end of intravenous treatment in the microbiologic modified intent-to-treat (ITT) population. Primary end point for European Medicines Agency (EMA) criteria was microbial eradication at test-of-cure visit in the microbiologic modified ITT and microbiologic evaluable...Continue Reading

Citations

Sep 6, 2018·Journal of Clinical Pharmacology·Ryan L Crass, Manjunath P Pai
Sep 13, 2018·Expert Review of Anti-infective Therapy·Matteo BassettiAlessandro Russo
Aug 15, 2018·Expert Opinion on Drug Metabolism & Toxicology·Rodrigo M BurgosLarry H Danziger
Aug 8, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Evangelos J Giamarellos-BourboulisMatteo Bassetti
Oct 30, 2018·Expert Review of Anti-infective Therapy·Owen R AlbinKeith S Kaye
Oct 10, 2018·Current Opinion in Infectious Diseases·Philippe Montravers, Matteo Bassetti
Nov 18, 2018·Expert Review of Clinical Pharmacology·Daniele Roberto GiacobbeClaudio Viscoli
Dec 7, 2018·Current Opinion in Pediatrics·James B WoodC Buddy Creech
Jan 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ilias KaraiskosHelen Giamarellou
Feb 23, 2019·Journal of the Pediatric Infectious Diseases Society·Pranita D Tamma, Alice J Hsu
Mar 13, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Keith S KayeEvelyn J Ellis-Grosse
Sep 13, 2018·JAMA : the Journal of the American Medical Association·Patrick N A HarrisUNKNOWN MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)
Feb 5, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George H TalbotUNKNOWN Infectious Diseases Society of America
Jul 3, 2019·Journal of Clinical Medicine·Nicola PetrosilloGuido Granata
Aug 6, 2019·International Journal of Urology : Official Journal of the Japanese Urological Association·Hiroyuki KitanoAkio Matsubara
Aug 17, 2019·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Michelle MahonySean E Kennedy
Jun 1, 2019·FEMS Microbiology Reviews·Mark LawsKhondaker Miraz Rahman
Sep 11, 2019·Current Infectious Disease Reports·Stephanie HoConan MacDougall
Oct 3, 2019·Current Opinion in Infectious Diseases·Antonio VenaMatteo Bassetti
Dec 5, 2019·Expert Review of Anti-infective Therapy·Nicola PetrosilloFabrizio Taglietti
Sep 19, 2019·Future Microbiology·Richard J VickersMark H Wilcox
Jan 15, 2020·Current Infectious Disease Reports·Mandee NovalEmily Heil
Nov 19, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ryan K ShieldsM Hong Nguyen
Dec 25, 2019·Journal of the Pediatric Infectious Diseases Society·Kathleen ChiotosPranita D Tamma
Apr 17, 2020·Expert Review of Anti-infective Therapy·Andrea NovelliMario Tumbarello
Apr 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dafna YahavDaniel Shepshelovich
Dec 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sean N AvedissianMarc H Scheetz
Jul 10, 2018·The Journal of Antimicrobial Chemotherapy·Menglan ZhouYingchun Xu
May 2, 2019·Frontiers in Medicine·Matteo BassettiDaniele Roberto Giacobbe
May 16, 2019·Nature Reviews. Nephrology·Tina Z WangDavid P Calfee
Jul 28, 2020·Expert Opinion on Pharmacotherapy·Mohamad MoussaAthanasios Papatsoris
Aug 28, 2020·Nature Reviews. Urology·Florian M E WagenlehnerZafer Tandogdu
Nov 1, 2018·Current Opinion in Infectious Diseases·Mario TumbarelloHelen Giamarellou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.